The performance of tuberculin skin test (TST) and interferon-γ release assays (IGRAs) in predicting tuberculosis (TB).
Fore scores $75M Series D, tees up new leadership with ex-Elevation CEO Shawn Leland at the helm — for now
Fore Biotherapeutics has reeled in a $75 million Series D, and its CEO Matthew Ros is walking off the course for “other professional pursuits,” the